As well as the two fatal outcomes reported, there were 242 serious reports and 267 categorised as non-serious
The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated
Below are observed minimum, median, and maximum annual funding levels per employee from our 2026 Annual Lifestyle Benefits Benchmark Report, based on 2025 program data
The FDA has issued public communications addressing concerns associated with compounded semaglutide and tirzepatide products
Nutrition for optimal lactation
Global GLP-1 Receptor Agonist Market Segmentation 1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs 2) By Route Of Administration: Parenteral, Oral 3) By End Users: Hospitals, Surgical Clinics, Other Users What Is The Driver Of The GLP-1 Receptor Agonist Market